Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer.
Santo G, Di Santo G, Sviridenko A, Bayerschmidt S, Wirth L, Scherbauer F, Lehmann P, von Guggenberg E, Decristoforo C, Heidegger-Pircher I, Bektic J, Virgolini I. Santo G, et al. Among authors: bektic j. Eur J Nucl Med Mol Imaging. 2024 Dec;52(1):354-365. doi: 10.1007/s00259-024-06905-5. Epub 2024 Sep 3. Eur J Nucl Med Mol Imaging. 2024. PMID: 39225826 Free PMC article.
Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.
Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, Roig LG, Kendler D, von Guggenberg E, Bektic J, Horninger W, Virgolini IJ. Uprimny C, et al. Among authors: bektic j. Eur J Nucl Med Mol Imaging. 2017 May;44(5):765-775. doi: 10.1007/s00259-016-3578-z. Epub 2016 Nov 29. Eur J Nucl Med Mol Imaging. 2017. PMID: 27900519
The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates.
Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, Decristoforo C, Uprimny C, Lukas P, Horninger W, Virgolini I. Scarpa L, et al. Among authors: bektic j. Eur J Nucl Med Mol Imaging. 2017 May;44(5):788-800. doi: 10.1007/s00259-016-3609-9. Epub 2017 Jan 12. Eur J Nucl Med Mol Imaging. 2017. PMID: 28083690 Clinical Trial.
Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
Uprimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, Nilica B, Maffey-Steffan J, di Santo G, Bektic J, Horninger W, Virgolini IJ. Uprimny C, et al. Among authors: bektic j. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1647-1655. doi: 10.1007/s00259-017-3743-z. Epub 2017 Jun 6. Eur J Nucl Med Mol Imaging. 2017. PMID: 28589253
The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up.
Maffey-Steffan J, Scarpa L, Svirydenka A, Nilica B, Mair C, Buxbaum S, Bektic J, von Guggenberg E, Uprimny C, Horninger W, Virgolini I. Maffey-Steffan J, et al. Among authors: bektic j. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):695-712. doi: 10.1007/s00259-019-04583-2. Epub 2019 Nov 27. Eur J Nucl Med Mol Imaging. 2020. PMID: 31776632 Free PMC article.
Correction to: The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up.
Maffey-Steffan J, Scarpa L, Svirydenka A, Nilica B, Mair C, Buxbaum S, Bektic J, von Guggenberg E, Uprimny C, Horninger W, Virgolini I. Maffey-Steffan J, et al. Among authors: bektic j. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):740. doi: 10.1007/s00259-019-04660-6. Eur J Nucl Med Mol Imaging. 2020. PMID: 31863137 Free PMC article.
Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study.
Kafka M, Horninger A, di Santo G, Virgolini I, Neuwirt H, Unterrainer LM, Kunte SC, Deiss E, Paffenholz P, Heidenreich A, Rasul S, Einspieler H, Shariat SF, Rajwa P, Dozauer R, Tsaur I, Medlock E, Rölz N, Rausch S, la Fougère C, Trautwein N, Roesch MC, Merseburger AS, Zattoni F, Sepulcri M, Ladurner M, Bektic J, Gandaglia G, Horninger W, Heidegger I. Kafka M, et al. Among authors: bektic j. Eur Urol Oncol. 2024 Jun;7(3):421-429. doi: 10.1016/j.euo.2023.07.018. Epub 2023 Aug 19. Eur Urol Oncol. 2024. PMID: 37604763 Free article.
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.
Heidegger I, Massoner P, Eder IE, Pircher A, Pichler R, Aigner F, Bektic J, Horninger W, Klocker H. Heidegger I, et al. Among authors: bektic j. J Steroid Biochem Mol Biol. 2013 Nov;138:248-56. doi: 10.1016/j.jsbmb.2013.06.002. Epub 2013 Jun 20. J Steroid Biochem Mol Biol. 2013. PMID: 23792785 Free PMC article. Review.
88 results